Last reviewed · How we verify

NCT07517068

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

Active, enrolled EARLY_PHASE1 Last updated 8 April 2026
What this trial tests

EARLY_PHASE1 trial testing ACETAZOLAMIDE oral capsule in Hypoxemia in 19 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
17 September 2025
Primary endpoint
15 June 2026
15 December 2026

Quick facts

Lead sponsorUniversity of California, Riverside
PhaseEARLY_PHASE1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposebasic science
Enrollment19
Start date17 September 2025
Primary completion15 June 2026
Estimated completion15 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, Riverside

Who can join

Adults 18 to 65, any sex, with Hypoxemia or Acute Mountain Sickness (AMS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ACETAZOLAMIDE oral capsule

Trials testing the same drug.

Other recruiting trials for Hypoxemia

Currently open trials in the same condition.

Other University of California, Riverside trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07517068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing